Select the drug indication to add to your list


Only 4 drugs may be compared at once

Generic Name and Formulations:

Exenatide ext-rel 2mg; pwd for SC inj after reconstitution.

Select therapeutic use:

Indications for BYDUREON:

Adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes.

Limitations Of use:

Not recommended as first-line therapy for patients inadequately controlled on diet and exercise. Not a substitute for insulin. Not for treating type 1 diabetes or diabetic ketoacidosis. Not studied in combination with insulin or with history of pancreatitis.


Give by SC inj in abdomen, thigh, or upper arm. Inject immediately after mixing. 2mg once every 7 days (weekly). Changing from Byetta: discontinue, then start Bydureon.


Not recommended.


History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.


Risk of thyroid C-cell tumors possible; monitor. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of anaphylaxis or angioedema with another GLP-1 agonist; monitor closely. Severe GI disorders, renal impairment (CrCl <30mL/min), end-stage renal disease: not recommended. Renal transplantation. Moderate renal impairment. Elderly. Pregnancy. Nursing mothers.


Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May delay absorption of oral drugs (eg, acetaminophen). Monitor INR more frequently with warfarin.

See Also:


Pharmacological Class:

Glucagon-like peptide-1 (GLP-1) receptor agonist.

Adverse Reactions:

Nausea, diarrhea, headache, vomiting, constipation, dyspepsia, inj site reactions; acute kidney injury, renal impairment, pancreatitis (may be fatal), hypersensitivity reactions (discontinue if occur), possible antibody formation (glycemic response may be attenuated); BCise: also inj site nodules.

Generic Availability:


How Supplied:

Single-dose trays—4 (each contains 1 vial, 1 prefilled syringe with diluent + supplies); Single-dose pens—4 (each contains 1 Bydureon Pen + 1 needle); BCise single-dose autoinjectors—4

BYDUREON 4 pens of 2mg/pen kits (Qty:1)

appx. price $683.00